Active Research and Trial Studies

---

• Steven E. Arnold, MD
• Daniel Weintraub, MD

---

Steven E. Arnold, MD

• Targeted Proteomics of Resilient Cognition in Aging (NIH/NIA)
• Plasma and CSF Biomarkers as Diagnostics for Alzheimer’s Decline Disease II: Validation, Disease Specificity, and Prediction of Cognitive Decline (Pfizer Alliance)
• The Effects of Donepzil on Regional Cerebral Blood Flow in Early Alzheimer’s Disease (Pfizer)
• Amyloid Imaging, VMCI, and Analysis for ADNI (University of California, San Diego)
• Neurobiologic Study of Psychological Distress and Dementia (NIH: Rush Univ)
• Effect of LY2062430, and Anti-Amyloid Beta Monoclonal Antibody, on the progression of Alzheimer's disease as compare with Placebo-LZAM Study (Eli Lilly)
• Bapineuzumab (Elan Pharmaceuticals, Inc)
• ACRIN PA 4003: Evaluation of the ability of novel 18f amyloid ligands to distinguish patients with a clinical diagnosis of Alzheimer's Disease for cognitively normal elderly individuals. (American College of Radiology ACR)
• IgIV: A Randomized, Double-Blind, Placebo-controlled, Two Dose-arm, parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IgIV) for the Treatment of Mild-to moderate Alzheimer's Disease. (Baxter and University of California, San Diego)
• Evaluation Of Event-related Potentials As A Method To Diagnose Alzheimer’s Disease by use of   COGNISION™ System to collect event-related potential (ERP) data. (Neurontrix, Inc.)

Daniel Weintraub, MD

• Citalopam Treatment for Agitation in Alzheimer Dementia. CITAD Study (NIH and Johns Hopkins University)
• Naltrexone for Impulse Control Disorders in Parkinson’s Disease (Michael J. Fox Foundation for Parkinson’s Research)
• Rivastigmine for Mild Cognitive Impairment in Parkinson’s Disease (Novartis Pharmaceuticals)

Participated Studies on Memory Disorder - please go to link: http://www.pennadc.org/